Previous Close | 2.0200 |
Open | 2.0500 |
Bid | 2.0600 x 0 |
Ask | 2.0900 x 0 |
Day's Range | 2.0500 - 2.1100 |
52 Week Range | 1.5500 - 3.9800 |
Volume | |
Avg. Volume | 109,796 |
Market Cap | 144.75M |
Beta (5Y Monthly) | 1.46 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.3800 |
Earnings Date | May 13, 2024 - May 17, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 4.50 |
Bill Radvak to transition to Board Advisor following decision to not stand for re-election to NervGen's Board of DirectorsAnnual General Meeting of Shareholders to be held on June 4, 2024Vancouver, British Columbia--(Newsfile Corp. - May 7, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that its Management Information Circular
Vancouver, British Columbia--(Newsfile Corp. - April 25, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that it has engaged Russo Partners LLC ("Russo Partners"), a New York based full-service strategic communications firm to provide media and public relations and related services for the Company.Russo Partners was engaged for
Anticipated completion of enrollment of the chronic cohort in the Phase 1b/2a clinical trial in Q2 2024CA$23 million bought deal financing completed in March 2024 provides expected cash runway through Q3 2025 Fast Track designation granted by U.S. Food and Drug Administration (FDA) for NVG-291 in spinal cord injuryVancouver, British Columbia--(Newsfile Corp. - April 17, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) a clinical-stage biotech company dedicated to developing innovative so